Prognostic factorsofsurvival inarandomizedphaseIIItrial (MPACT)of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

Oncologist

Volumn 20, Issue 2, 2015, Pages 143-150

  Tabernero, Josep ^a   Gabrielachiorean, E ^b   Infante, Jeffrey R ^c   Hingorani, Sunil R ^d   Ganju, Vinod ^e   Weekes, Colin ^f   Scheithauer, Werner ^g   Ramanathan, Ramesh K ^h   Goldstein, David ⁱ   Penenberg, Darryl N ^j   Romano, Alfredo ^j   Ferrara, Stefano ^j   Von Hoff, Daniel D ^k  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d USA   (United States)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h MAYO CLINIC   (United States)

ⁱ PRINCE OF WALES HOSPITAL   (Australia)

^j CELGENE CORPORATION   (United States)

^k HonorHealth and the Scottsdale Lincoln Health Network   (United States)

more..

Author keywords

Gemcitabine; Nab Paclitaxel; Pancreatic cancer; Prognostic factors

Indexed keywords

CARBOHYDRATE ANTIGEN; GEMCITABINE; PACLITAXEL; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADULT; ARTICLE; FEMALE; FOLLOW UP; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS METASTASIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; LIVER NEOPLASMS; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; SECONDARY;

ADULT; AGED; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 84922732378     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0394     Document Type: Article

References (25)

1. GLOBOCAN. 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at http://globocan.iarc.fr/. Accessed September 30, 2014.
2. Howlader N, Noone AM, Krapcho M et al. SEER cancer statistics review, 1975-2010. Available at http://seer.cancer.gov/csr/1975_2010/. Accessed September 30, 2014.
3. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25: 1960-1966.
4. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-1825.
5. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-1703.
6. Andersson B, Aho U, Pendse M et al. Gemcitabine treatment in pancreatic cancer-prognostic factors and outcome. Ann Gastroenterol 2007;20: 130-137.
7. Bauer TM, El-Rayes BF, Li X et al. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: A pooled analysis of 6 prospective trials. Cancer 2013;119:285-292.
8. Inal A, Kos FT, Algin E et al. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: Retrospective analysis of amulticenter study. J BUON 2012;17:102-105.
9. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
10. Zhang DX, Dai YD, Yuan SX et al. Prognostic factors in patients with pancreatic cancer. Exp Ther Med 2012;3:423-432.
11. Scheithauer W, Von Hoff DD, Ramanathan RK et al. Dose delivery in a phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone for patients with metastatic adenocarcinoma of the pancreas [abstract 2.586]. Presented at: European Cancer Congress; September 27-October 1, 2013; Amsterdam, The Netherlands.
12. Hess V, Glimelius B, Grawe P et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. LancetOncol 2008; 9:132-138.
13. Eichbaum MH, Kaltwasser M, Bruckner T et al. Prognostic factors for patients with liver metastases frombreastcancer.BreastCancer ResTreat 2006;96: 53-62.
14. Maltoni M, Pirovano M, Scarpi E et al. Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer 1995;75:2613-2622.
15. Garrido-Laguna I, Janku F, Vaklavas C et al. Validation of the Royal Marsden Hospital prognostic score in patients treated in the phase I clinical trials program at theMDAnderson Cancer Center. Cancer 2012;118:1422-1428.
16. Stocken DD, Hassan AB, Altman DG et al. Modelling prognostic factors in advanced pancreatic cancer. Br J Cancer 2008;99:883-893.
17. Boeck S, Stieber P, Holdenrieder S et al. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006;70:255-264.
18. Saad ED, Machado MC, Wajsbrot D et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int JGastrointestCancer 2002;32: 35-41.
19. Goldstein D, El Maraghi RH, Hammel P et al. Updated overall survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. J Clin Oncol 2014;32(suppl 3):178a.
20. Von Hoff DD, Ramanathan RK, Borad MJ et al. Gemcitabine plus nab-paclitaxel isanactiveregimen in patients with advanced pancreatic cancer: A phase I/II trial. J Clin Oncol 2011;29:4548-4554.
21. Infante JR, Matsubayashi H, Sato N et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007;25:319-325.
22. Sinn M, Sinn BV, Striefler JK et al. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: Results from the CONKO-001 study. Ann Oncol 2014;25:1025-1032.
23. Hidalgo M, Plaza C, Illei PB et al. SPARC analysis in the phase III MPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone for patients with metastatic pancreatic cancer (PC). Ann Oncol 2014;25(suppl 2):ii106.
24. Ma C, Bandukwala S, Burman D et al. Interconversion of three measures of performance status: An empirical analysis. Eur J Cancer 2010;46: 3175-3183.
25. Thomassen I, Lemmens VE, Nienhuijs SW et al. Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin:Apopulation-based study. Pancreas 2013;42: 72-75.